# KT-200

Source: https://onco.cc/drugs/kt-200/  
OnCo record `kt-200` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

KT-200 is an experimental molecular glue degrader from Kymera Therapeutics, in preclinical development for CCNE1-amplified or over-expressed cancers and breast cancer.

## Summary

KT-200 is a molecular glue degrader (oral) from Kymera Therapeutics, with Gilead Sciences as licensee. An oral molecular glue degrader designed to remove CDK2 while sparing other CDK family proteins; CDK2 partners cyclin E and drives CCNE1-amplified and over-expressed cancers. Its furthest stage is preclinical development, for CCNE1-amplified or over-expressed cancers and breast cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Gilead is running IND-enabling studies toward an IND filing in 2027 (Kymera 8-K, 29 Oct 2026). It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: KT-200
- Modality: Molecular glue degrader (oral)
- Mechanism: An oral molecular glue degrader designed to remove CDK2 while sparing other CDK family proteins; CDK2 partners cyclin E and drives CCNE1-amplified and over-expressed cancers.

## Sources

- Kymera Therapeutics: biospace.com: https://www.biospace.com/press-releases/kymera-therapeutics-announces-gilead-sciences-option-exercise-to-license-kt-200-oral-cdk2-molecular-glue-degrader-development-candidate
- Kymera Therapeutics: biospace.com: https://www.biospace.com/press-releases/kymera-therapeutics-announces-gilead-sciences-option-exercise-to-license-kt-200-oral-cdk2-molecular-glue-degrader-development-candidate
- Kymera Therapeutics: sec.gov: https://www.sec.gov/Archives/edgar/data/1815442/000119312526436965/kymr-ex99_1.htm

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [CDK2](https://onco.cc/targets/cdk2/)
- companies: [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/), [Kymera Therapeutics](https://onco.cc/companies/kymera/)

---
JSON: https://onco.cc/api/v1/entities/kt-200.json